Polycystic ovary syndrome: important underrecognised cardiometabolic risk factor in reproductive-age women by Pavičić Baldani, Dinka et al.
Review Article
Polycystic Ovary Syndrome: Important Underrecognised
Cardiometabolic Risk Factor in Reproductive-Age Women
Dinka Pavicic Baldani,1 Lana Skrgatic,1 and Roya Ougouag2
1Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Clinical Hospital Centre,
School of Medicine, University of Zagreb, Petrova 13, 10 000 Zagreb, Croatia
2School of Medicine, Medical Studies in English, University of Zagreb, Sˇalata 3, 10 000 Zagreb, Croatia
Correspondence should be addressed to Lana Skrgatic; lana.skrgatic@zg.t-com.hr
Received 14 December 2014; Accepted 26 March 2015
Academic Editor: Manuel Estrada
Copyright © 2015 Dinka Pavicic Baldani et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder amongst women of reproductive age. Although PCOS
is diagnosed exclusively based on reproductive criteria, it is also ametabolic disorder. Insulin resistance, impaired glucose tolerance,
type 2 diabetesmellitus, obesity, and dyslipidemia aremore common inwomenwith PCOS than in age-comparable womenwithout
PCOS. Many of the metabolic abnormalities that manifest in PCOS are worsened by the concurrent incidence of obesity. However,
some of these metabolic perturbations occur even in lean women with PCOS and therefore are rightfully recognized as intrinsic
to PCOS. The intrinsic factors that produce these metabolic disturbances are reviewed in this paper. The consequences of obesity
and the other metabolic aberrations are also discussed. The metabolic perturbations in PCOS patients lead to chronic low-grade
inflammation and to cardiovascular impairments that heighten the risk of having cardiovascular disease. Even thoughmany studies
have shown an elevation in surrogate biomarkers of cardiovascular disease in PCOS women, it is still not clear to what extent and
magnitude the elevation precipitates more frequent and earlier events.
1. Introduction
Polycystic ovary syndrome (PCOS) is the most common
endocrine disorder amongst women of reproductive age.
It is a heterogeneous disorder of uncertain etiology, but
there is strong evidence that complex interactions between
genetic, environmental, and behavioral factors contribute to
causing this syndrome [1]. PCOS affects as many as 10%
of reproductive-age women when using the NIH criteria
for diagnosis, and up to 18% of reproductive-age women
are diagnosed with PCOS as per the Rotterdam criteria [2].
Nevertheless, at least 70%of PCOS cases remain undiagnosed
in primary care [3].
Although the diagnosis of PCOS is based exclusively on
reproductive criteria (hyperandrogenism, oligo/anovulation,
and/or PCO on ultrasound) [4], and management tends to
focus primarily on treatment of infertility and hirsutism [5],
PCOS is also a metabolic disorder. Women with PCOS have
an increased risk of presenting with insulin resistance (IR)
[6], impaired glucose tolerance (IGT) [7], type 2 diabetes
mellitus (DM2) [7], obesity [6], and dyslipidemia [8]. In
addition to presenting with these traditional risk factors for
CVD, women with PCOS also show evidence of an increase
of nontraditional, novel CVD risk factors, such as subclinical
atherosclerosis [9] and an elevation in inflammatory markers
[10]. As PCOS seems to be dominated by metabolic con-
sequences, both as a consequence of the condition and as
a vector for further complications, including DM2, CVD,
and the exacerbation of the reproductive features of the
syndrome (hirsutism and an/oligoovulation) [5], it is evident
that research on the metabolic and cardiometabolic features
of PCOS is needed. The present review is a contribution
to this overall effort. The sections that follow discuss the
cardiometabolic aspects of PCOS, their potential causes, their
associated risks, and possible screening measures.
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Table 1: PCOS diagnostic criteria, adapted from Teede et al. 2010 [5].
NIH 1990 Rotterdam 2003 AE-PCOS Society 2006
Both of the following*:
(i) chronic anovulation, documented by
oligo-or amenorrhea
(ii) clinical and/or biochemical signs of
hyperandrogenism (with exclusion of other
etiologies, e.g., congenital adrenal
hyperplasia)
with or without PCO on ultrasound
At least two of the following*:
(i) chronic anovulation, documented by
oligo-or amenorrhea
(ii) clinical and/or biochemical signs of
hyperandrogenism
(iii) polycystic ovaries (by ultrasound)
(i) Clinical and/or biochemical signs of
hyperandrogenism and
at least one of the following*:
(i) ovarian dysfunction
(oligo/anovulation and/or polycystic
ovarian morphology)
*After exclusion of the diseases that produce a similar clinical picture.
2. Methods
An extensive literature search was conducted to review
publications from the late 1980s to the present.Online sources
of medical databases included the US National Library
of Medicine (NLM), the National Center for Biotechnol-
ogy Information (NCBI) at the NLM, the Helios Group
Central Medical Library, PubMed, and Medscape. The
search was conducted with a combination of terms that
included “PCOS,” “cardiometabolic,” “cardiovascular dis-
ease,” “metabolic syndrome,” “insulin resistance,” and “obe-
sity” that were assumed to be relevant. Articles were also
selected among references in the published papers found in
the automated searches. Studies and review articles covering
the focused areas were then selected.
3. Diagnostic Criteria of PCOS and Different
PCOS Phenotypes
Commonly Used Criteria. Three different sets of criteria
have been used for the diagnosis of PCOS for the past
two decades: the National Institutes of Child Health and
Human Development (NICHD) or what is known as the
NIH criteria (developed in 1990), the Rotterdam criteria
(adopted at a PCOS consensus meeting held in 2003), and
the Androgen Excess (AE) and PCOS Society (AE-PCOS)
criteria (proposed in 2006) [5].These criteria are summarized
in Table 1.
The different diagnostic criteria create several phenotypes
of PCOS. Even before the Rotterdam criteria were adopted,
it was evident that different subgroups of PCOS existed
and it was even suggested that these subgroups differed
metabolically [6]. One extensive review by Moran and
Teede sought to compare the metabolic profiles among these
different reproductive phenotypes [11]. For simplification,
the phenotypes were divided into four diagnostic groups:
phenotype A (NIH PCOS of biochemical/clinical hyper-
androgenism and oligo/anovulation with PCO); phenotype
B (NIH PCOS of biochemical/clinical hyperandrogenism
and oligo/anovulation without PCO); phenotype C (non-
NIH PCOSwith biochemical/clinical hyperandrogenism and
PCO but with normal ovulation); phenotype D (non-NIH
PCOS with oligo/anovulation and PCO but without any
biochemical/clinical hyperandrogenism) [11]. The diagnostic
criteria of each of these four phenotypes are summarized in
Table 2.
Table 2: Diagnostic phenotypes of PCOS, adapted fromMoran and
Teede (2009) [11].
Phenotype A NIH PCOS: hyperandrogenism andoligo/anovulation with PCO
Phenotype B NIH PCOS: hyperandrogenism andoligo/anovulation without PCO
Phenotype C Non-NIH PCOS: hyperandrogenism with PCObut with normal ovulation
Phenotype D Non-NIH PCOS: no hyperandrogenism but witholigo/anovulation and with PCO
PCOS is also acknowledged as a metabolic disorder. Car-
diometabolic features of PCOS are summarized as follows:
visceral obesity,
insulin resistance and hyperinsulinemia,
risk of type II diabetes,
disturbed secretion from adipocytes (adipokines,
proinflammatory, and macrophage-derived factors),
dyslipidemia,
vascular endothelium dysfunction,
prothrombotic state,
atherosclerosis.
Most studies comparing the two subtypes of NIH PCOS,
phenotypes A and B, report that women diagnosed under
phenotype A present with few, if any, differences inmetabolic
profiles compared with women having phenotype B PCOS
[11]. Similarly, most studies limiting comparison to only
non-NIH subtypes, phenotypes C and D, also agree that
womenwith phenotypeCPCOS do not present with different
metabolic risks compared towomenwith phenotypeDPCOS
[11]. However, most studies conclude that women with NIH
PCOS (phenotypes A and B) present with more adverse
metabolic profiles (including higher IR, increased prevalence
of metabolic syndrome, and more adverse lipid profiles) than
those with non-NIH PCOS (phenotypes C and D) [11].
Studies comparing women categorized under the NIH
and non-NIH PCOS groups, but only after matching the
subjects for BMI andWHR, found that the metabolic profiles
(degree of IR, metabolic syndrome prevalence, and lipid
profiles) are similar in the NIH and non-NIH PCOS women
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Figure 1: Pathophysiology of metabolic disturbances in PCOS.
CVD, cardiovascular disease; TG, triglycerides; HDL-C, high-
density lipoprotein cholesterol; VLDL-C, very-low-density lipopro-
tein cholesterol; CRP, C-reactive protein; TNF-𝛼, tumor necrosis
factor-alpha; IL-6, interleukin-6; FMD, flow-mediated dilatation;
IMT, intima-media thickness; SHBG, sex hormone binding globu-
lin; LH, luteinizing hormone; DM, diabetes mellitus.
[11]. These results suggest that although NIH phenotypes
present with more adverse metabolic profiles, the worse
metabolic profile is not an inherent feature of NIH PCOS
but is related to excess adiposity, particularly abdominal
adiposity, which is more common in NIH PCOS groups
[11]. The interactions between the different pathophysiologic
factors of PCOSwithmetabolic syndrome are summarized in
Figure 1.
The etiology of PCOS remains uncertain; however, due
to a variety of predisposing genes that interact with envi-
ronmental and lifestyle factors, PCOS is considered a com-
plex genetic disorder [12]. A large number of population
studies have focused on discovering genes that influence the
development of PCOS using the candidate gene approach
[13], but their findings have been mostly irreproducible. It is
possible that a particular gene influences PCOS in one ethnic
group but not in the others [12]. Various PCOS phenotypes
presumably result from the interaction between multiple
predisposing genomic variants, each exerting only minor
effects, and strong environmental influences.
4. Cardiometabolic Aspects of PCOS
4.1. Obesity in PCOS. The prevalence of obesity among
women with PCOS in the USA is 70 to 80%, almost twice as
much as in the general US female population [6, 14]. Most
studies report the prevalence of obesity in affected women
outside theUSA to be between 38 and 50% [6, 14]. Differences
in diagnostic criteria, environmental factors, ethnicity, and
lifestyle contribute to these variations [6, 15, 16]. Although less
obesity is reported outside the USA, the prevalence of obesity
among PCOSwomen outside the USA is still higher than that
of women in the general population outside the USA [14].
As an example, 38% of Italian PCOS women are reported to
be obese [14], but the reported prevalence of obesity in the
general Italian female population is only 8% [17], highlighting
a possible contribution of PCOS per se, in addition to lifestyle
and other factors cited above, to the pathogenesis of obesity.
4.1.1. Consequences of Obesity in PCOS. Obesity plays a role
in the expression of metabolic features and other clinical
manifestations of PCOS [6, 8, 18]. IR appears in normal
weight PCOS women, but the frequency and magnitude
increasewith obesity [19, 20].Themagnitude of IR, quantified
in one study by the insulin to glucose ratio, demonstrated
a strong, positive, and linear correlation with body mass
index (BMI) of the PCOS subjects [20]. Hepatic insulin
resistance, characterized by reduced sensitivity to insulin’s
suppression of endogenous glucose production, only occurs
in obese PCOS women [21]. Obese PCOS women also have
a 10-fold increase in their risk of suffering from DM2 and
a 7-fold increase of IGT compared with normal weight
(BMI < 25 kg/m2) PCOS women [22]. An accelerated rate
of conversion from IGT to DM2 is strongly dependent upon
BMI [23].
Obesity in PCOS increases the patient’s risk of developing
cardiovascular disease. Among PCOSwomen, the prevalence
of the metabolic syndrome, as in the general population,
increases with increasing BMI and is highest in obese
women with PCOS [17]. Studies report the prevalence of
the metabolic syndrome in PCOS women in the USA to
be 43–47%, twice more than in the age- and BMI-matched
control population, suggesting that PCOS per se, possibly by
promoting abdominal fat accumulation, increases the risk of
acquiring the metabolic syndrome [17]. The effect of obesity,
of causing chronic low-grade inflammation [24] with an
elevation of inflammatorymarkers (such as CRP, TNF-𝛼, and
IL-6) that increase the risk of cardiovascular disease [25], is
even more pronounced in PCOS. In PCOS and non-PCOS
women, levels of TNF-𝛼 [26, 27], IL-6, andCRP [27] correlate
directly with BMI, but overweight and obese PCOSwomen in
some studies have presented with significantly higher levels
of these inflammatorymarkers than their BMI-matched non-
PCOS counterparts [10, 27].
4.1.2. The Pathogenesis of Obesity in PCOS. The pathogenesis
of obesity in PCOS is likely multifactorial [28].
One study reported that, in a group of lean PCOSwomen,
serum glycerol levels, which reflect lipolytic activity, were
lower than glycerol levels in BMI-matched control women
[28]. The same authors also showed that the subcutaneous
adipocytes of the lean PCOS women were larger in size
and exhibited a lower response to catecholamine-stimulated
lipolysis than the adipocytes of the BMI-comparable control
women, suggesting that decreased lipolysis of subcutaneous
adipocytes is an early alteration in PCOS, leading to enlarged
subcutaneous fat cells and later to the development of obesity
[28].
Another contributor to the high prevalence of obesity in
PCOS might be mutations in the peroxisome proliferator-
activated receptor-𝛾 gene [29]. A higher frequency of C→
T substitution in exon 6 of the peroxisome proliferator-
activated receptor-𝛾 gene has been reported in PCOS
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women than in BMI-matched controls [29].This substitution
enhances adipogenesis and increases the size of subcutaneous
adipocytes, possibly leading to obesity [29].
Several studies also report that women with PCOS [30,
31] or with PCO morphology on ultrasound [32] have a
higher prevalence of bulimic behavior, in part because of
increased androgens [33], which increase appetite and inhibit
impulse control [33]. After treatment with flutamide [34]
or with antiandrogenic oral contraceptives [35], a reduction
of binge eating and meal-related hunger, respectively, has
been reported in bulimic women, supporting the idea that
androgensmay play a role in appetite dysregulation and in the
development of obesity in PCOS [33]. Women with PCOS,
in comparison to BMI-matched controls, also have reduced
secretion of the gastrointestinal satiety peptide cholecys-
tokinin [30] and have dysregulated secretion of the appetite-
regulating gut hormone ghrelin [36, 37] that is independent
of diet. These alterations may cause the reduction in satiety
that has been reported by PCOS patients in comparison to
BMI-matched control women [30, 37].
Additionally, it is widely believed that ghrelin’s actions
are mediated centrally by neuropeptide Y (NPY) and by the
system of NPY fibers [36]. NPY acts centrally to increase
appetite [38]. In a study on PCOS women, NPY levels were
reported to be higher in obese and lean women with PCOS
than in BMI-comparable control women [39].
4.1.3. The Distribution of Adipose Tissue in PCOS. Subcu-
taneous abdominal fat and visceral fat both contribute to
the development of IR [40]. Visceral fat furthermore creates
a chronic low-grade inflammation [41] and is a surrogate
marker for ectopic fat accumulations [42], which are respon-
sible for many of the harmful effects of obesity [43, 44].
Many studies, based on anthropometric measures such as the
waist-to-hip (WHR) ratio, suggest that there is a tendency
in PCOS towards the accumulation of fat in these harmful
areas such as the abdominal visceral region. It is known
that fat distribution in the abdominal area is associated
with more adverse metabolic profiles in PCOS [11, 45].
However, there is debate as to whether abdominal fat storage
occurs more in PCOS than in weight-matched controls.
Several studies quantifying abdominal subcutaneous and
visceral adipose tissue by MRI [45, 46] and DEXA (which
only quantifies total central abdominal fat) [47] found no
difference in the volume of total abdominal fat or visceral
fat between PCOS women and BMI-matched controls. On
the contrary, Dolfing et al. demonstrated even less visceral
fat accumulation in lean PCOSwomen compared tomatched
controls assessed by MRI [48]. However, in other studies,
MRI [42] showed an increase in visceral and subcutaneous
abdominal fat, and DEXA [49] showed an increase in the
proportion of upper body fat in PCOS women compared to
BMI-matched controls. The different results may depend on
the small number of patients and controls and may also be
related to the degree of obesity [42]. Studies in which the
majority [41, 42, 50] or all [49] of the women were nonobese
have reported a higher quantity of central abdominal fat
in PCOS women than in BMI-matched controls. Results
from a more highly powered study with over 200 patients
and controls evaluated by DEXA support the suggestion
that the disparities reported by different authors are related
to the degree of obesity [41]. When the 220 subjects from
the study were stratified according to BMI into obese and
nonobese subgroups, there was no difference in the quantity
of central abdominal fat between obese PCOS women and
obese control women, but when limiting the comparison
to the nonobese women, the quantity of central abdominal
fat was higher in nonobese PCOS women compared to the
quantity in nonobese control women [41].These observations
demonstrate that when obesity is present, most subjects
display abdominal obesity, independently of being afflicted
with PCOS or not [41]. However, when obesity is not present,
PCOS patients stock a higher portion of their total adiposity
in the abdominal region than do BMI-comparable controls
[41]. Abdominal adiposity may therefore be a risk factor
in nonobese PCOS women that confers on them adverse
metabolic profiles compared to their BMI-matched non-
PCOS counterparts [41]. Studies report that the quantity of
central abdominal fat positively correlates with the degree
of IR in nonobese PCOS women [41] and to the level of
inflammatory markers [50]. DEXA accurately quantifies fat
in different regions, is not operator dependent, and, unlike
MRI, can be used on large populations [41]. DEXA may
therefore be a useful screening tool for nonobese PCOS
women susceptible to central abdominal fat accumulation
and, hence, to the adversemetabolic complications associated
with centripetal fat distribution [11].
4.2. Insulin Resistance and Hyperinsulinemia. Insulin resis-
tance (IR) occurs in 30% of lean women with PCOS [8] and
95% of obese women with PCOS [51]. The presence of IR
in Mediterranean populations of PCOS patients is somewhat
less than that reported in other nations [52, 53]. South Asians
in particular have high prevalence of insulin resistance and
metabolic syndrome with central obesity in comparison with
other PCOS-related ethnic groups of a similar BMI [54].
African American and Hispanic women are more obese and
more prone to metabolic problems [55, 56].The ethnic origin
and cultural habits largely contribute to manifestations and
risks of insulin resistance in PCOS [7]. Overall, 60–80% of
women with PCOS present with elevated insulin levels [57–
60].
Insulin is also a major regulator of many enzymes
involved in lipoprotein metabolism [61, 62]. Resistance to
insulin may contribute, in part, to the dyslipidemia observed
in PCOS [16, 61]. A detailed description of the steps involved
in lipoprotein metabolism is beyond the scope of this review.
However, it has been proven that IR increases the hepatic
secretion of VLDL and decreases the elimination of VLDL
and of chylomicrons [19]. The persistence of VLDL and of
chylomicrons in the circulation provides a major source for
triglyceride (TG) production [62]. IR also leads to the more
rapid clearance of apolipoprotein-a, a constituent of HDL-
C, thus reducing the production and levels of HDL-C [62].
In several population-based studies, described in a paper by
Miccoli et al., measures of IR correlated positively with levels
of TG andVLDL-C and negatively with levels of HDL-C [62].
A study by Slowinska-Srzednicka and colleagues sought to
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elucidate the role of insulin resistance in the development of
lipid abnormalities in women susceptible to PCOS [63]. In
a group of women with polycystic ovaries, after adjustment
for age, BMI, and sex hormones, regression analysis showed a
strong positive association between fasting insulin levels and
TG and VLDL-C levels and a negative association between
fasting insulin levels and levels of the HDL constituent
apolipoprotein-a [63].
The high prevalence of insulin resistance in PCOS also
renders PCOS women 10 times more likely than controls to
develop gestational diabetes and up to 5 times more likely
to develop insulin-related complications such as spontaneous
abortion [8].
4.2.1. The Pathogenesis of Insulin Resistance in PCOS. The IR
of PCOS is in part independent of obesity; it is primarily
a result of intrinsic factors. A postbinding decrease in the
phosphorylation of the tyrosine residues and an increase in
the phosphorylation of the serine residues of the intracellular
domain of the insulin receptor cause resistance to insulin’s
metabolic actions [6]. An elevation in serine phosphorylation
not only decreases the responsiveness of the insulin receptor
to its substrate, but also enhances the activity of P450C17, the
key enzyme of adrenal and ovarian steroid synthesis [64].The
same defect in serine phosphorylation is therefore thought to
cause both IR and hyperandrogenism in a subgroup of PCOS
patients [6]. Other possible causes of insulin resistance in
PCOS include increased serine phosphorylation of the adap-
tor protein IRS-1 [6]. Serine phosphorylation of the latter dis-
rupts intracellular signaling necessary for the translocation of
GLUT4 into the plasma membrane [6]. Reduced expression
of GLUT4 has been demonstrated in the plasma membranes
of adipocytes of both lean and obese PCOS patients [65].
Increased activation of ERK1/2 pathways in muscle cells
of PCOS women may also be responsible for resistance
to insulin’s metabolic actions [6, 66]. Although ERK1/2
pathways are usually involved in insulin’s mitogenic actions
[6, 66], enhanced basal activation of ERK1/2 can also inhibit
the IRS-1 pathways necessary for GLUT4 translocation to
the plasma membrane [66]. Increased lipolysis in visceral
fat cells may contribute to the hepatic insulin resistance
observed in obese PCOS women [67]. Visceral fat cells of
PCOSwomen demonstrate an enhanced lipolytic response to
catecholamines [67]. Enhanced lipolysis of visceral fat raises
fatty acid and glycerol delivery to the portal vein and liver,
perturbing liver function, eventually leading to hepatic IR, as
well as to hepatic inflammation and to interference with the
production of SHBG [67].
4.3. Impaired Glucose Tolerance and Type 2 Diabetes. The
American Diabetes Association has designated PCOS as
a nonmodifiable risk factor for type 2 diabetes [68]. The
prevalence of IGT and DM2 in women with PCOS, assessed
in three large ethnically diverse US cross-sectional studies,
was 23–35% for IGT and 4–10% for DM2, that is, twice
the prevalence in age- and weight-matched healthy women
without PCOS [6]. The prevalence of IGT and DM2 among
PCOS women from other countries (Italy, Netherlands) was
also found to be significantly higher than the prevalence in
control women from the same region, although the overall
proportion of European PCOSwomen having IGT or DM2 is
nevertheless lower than that of US PCOS women affected by
these conditions [6]. Authors suggest that different diagnostic
criteria, diet, race, and ethnicity may account for the higher
prevalence of IGT and DM2 in US PCOS women [6, 16].
When the PCOS women from European and US studies were
stratified according to BMI and comparisons were limited
to women in comparable BMI categories, the differences in
the prevalence of IGT and DM2 between US and European
PCOS women still persisted but decreased, highlighting the
contribution of lifestyle to the disparities in IGT and DM2
observed between US and European women [6]. Addition-
ally, a study of two PCOS populations in the USA, one urban
ethnically diverse and one rural ethnically homogeneous,
showed similar proportions of women with IGT and DM2
in each of the two populations, therefore demonstrating that
PCOSmay be a more important risk factor for IGT and DM2
than factors such as race and ethnicity [69]. These general
tendencies towards a deterioration of glucose metabolism
have been confirmed by a meta-analysis indicating a higher
prevalence of IGT (odds ratio 2.54) and DM2 (odds ratio 4)
in PCOS women than in BMI-matched controls [7].
Studies have also reported higher conversion rates from
normal glucose tolerance (NGT) to IGT and from IGT to
DM2 in PCOS women [70, 71]. IGT is an independent
predictor of developing DM2 and CVD and of suffering
mortality from CVD [71]. Early identification and treatment
of IGT with lifestyle intervention and/or metformin have
been shown to improve outcomes [72]. These observations
have led experts at themost recent ESHRE/ASRM-sponsored
PCOS consensus workshop to suggest the implementation of
an annual screening of all PCOS women for IGT with the
OGTT [3, 73], the most sensitive test for assessing IGT in
PCOS [6].
Chronic hyperinsulinemia per se exacerbates IR, leading
to a higher demand for insulin production and eventually
to 𝛽-cell burnout, thereby accelerating the progression to
IGT and DM2 [5]. Although women with PCOS have higher
basal insulin secretion conditioned by chronic IR, they
demonstrate 𝛽-cell secretory defects, manifested by reduced
insulin secretory response to meals [74] and eventually an
overall secretion of insulin that is inadequate for the degree
of IR [75]. IR, 𝛽-cell secretory defects, and eventual 𝛽-cell
burnout contribute to the development of IGT and DM2 in
PCOS [74].
4.4. Adipokines. The increased incidence and severity of
cardiovascular risk factors and of metabolic disturbances in
PCOSmay be in part related to the abnormal production and
release of adipokines and inflammatory factors by adipose
tissue [8]. Although traditionally regarded as a storage organ,
emerging evidence also strongly suggests that adipose tissue
is an endocrine organ [8], whose altered function may
produce widespread cardiometabolic disturbances in PCOS.
It is believed that dysregulated adipocyte function and obesity
play a pathophysiological role in PCOS [5, 28].
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4.4.1. Leptin. Leptin, a protein secreted by adipocytes, sup-
presses an individual’s appetite and promotes energy expen-
diture [76]. Serum leptin levels are elevated in obese patients,
who are considered leptin resistant [76]. Hyperleptinemia
seems to be a positive risk factor for cardiovascular disease
[77–79]. Although some studies have found leptin levels to
be elevated in PCOS women compared to controls [80, 81],
the general consensus reported by the majority of published
studies is that there is no difference in circulating leptin
levels in PCOS subjects in comparison to BMI-matched
controls [82–90]. The different results might be explained
by differences in ethnicity, heterogeneity in criteria used
to classify PCOS, and low number of PCOS subjects and
controls [90, 91].
Most studies report that adiposity, quantified by BMI, is
the main correlative component and determinant of leptin
levels in PCOS women [82–90]. Leptin mRNA expression
in adipocytes did not differ between PCOS women and
BMI-matched controls [89], providing further evidence that
obesity, rather thanPCOS per se, affects leptin production and
circulating levels. After adjustment for BMI, some authors
report that leptin levels do correlate minimally with the free
androgen index [82, 83, 86, 92] but nevertheless do not differ
between visibly hirsute and nonhirsute women with PCOS
[82]. Most studies addressing leptin and insulin report that,
after adjustment for BMI, leptin levels in PCOS women do
not correlate with the chronic insulin levels [82, 85, 88, 89,
92], while others report that leptin levels in PCOS women
did correlate with measures of insulin resistance [81, 83].
However, in further support of findings that negate a signifi-
cant correlation between insulin resistance and leptin levels,
treatment of chronically hyperinsulinemic insulin resistant
PCOS women with the thiazolidinediones troglitazone [85]
or rosiglitazone [88] was shown to lower insulin levels but
did not alter leptin levels in these patients.
4.4.2. Adiponectin. Adiponectin, which is secreted exclu-
sively by adipose tissue, exerts insulin sensitizing actions
both indirectly [93] and directly by activating tyrosine
phosphorylation of the skeletal muscle insulin receptor [94].
Adiponectin levels are reduced in insulin resistance states
such as DM2 across all ethnic groups [95]. Low levels are
also associated with a faster progression towards DM2 in
at-risk individuals [95] and with higher risk of CHD in
women [96]. Low levels are also possibly associated with high
LH/FSH ratios and impaired ovulation because adiponectin
in normal levels reduces secretion of LH through AMPK
phosphorylation without affecting FSH secretion [97].
Ameta-analysis has demonstrated that adiponectin levels
are lower in PCOS women than in control women of
comparable BMI [98]. A more recent meta-analysis has
indicated that the T45G polymorphism in the adiponectin
gene is associated with PCOS [99]. Although few studies
exist focusing on high molecular weight adiponectin and the
earlier meta-analysis did not specifically evaluate levels of
high molecular weight (HMW) adiponectin [98], which is
considered to be amore potentmediator of insulin sensitivity
[100], it has been reported that levels of HMW adiponectin
and the ratio of HMW adiponectin to total adiponectin
are both lower in PCOS women than in age- and BMI-
comparable controls [101].
4.4.3. Visfatin. Visfatin is a cytokine secreted, among other
cell types, by adipocytes [102]. It stimulates glucose uptake
by cells, thus inducing insulin-mimetic effects [102]. A meta-
analysis established that plasma visfatin levels are signifi-
cantly increased in subjects with obesity, DM2, metabolic
syndrome, and CVD [103]. Furthermore, in diabetics, serum
visfatin levels increase with progressive 𝛽-cell deterioration
[104]. Haider et al. demonstrated that insulin inhibited vis-
fatin release from adipocytes in healthy subjects, suggesting
that elevated visfatin levels may reflect insulin resistance
[105].
Given visfatin’s insulin-mimetic actions, some authors
have suggested visfatin may be elevated to compensate for
insulin resistance [106] and to prevent further resistance
to insulin [107, 108]. However, elevated visfatin levels may
produce harmful effects. Rising visfatin levels correlate with
the degree of endothelial dysfunction, quantified by the
decline in flow-mediated vasodilation and impaired renal
clearance [109]. Visfatin activates nuclear transcription fac-
tor NF-𝜅B in vascular endothelial cells [110] and in lipid-
laden macrophages of atherosclerotic lesions [111], culmi-
nating in the activation of metalloproteinase-2 [110] and
metalloproteinase-9 [111, 112], leading to vascular inflamma-
tion and plaque destabilization, respectively.
In patients undergoing carotid endarterectomy or percu-
taneous coronary interventions, visfatin expression is higher
in the atherosclerotic lesions of symptomatic patients than
in the lesions of asymptomatic patients, further emphasizing
the role of this adipokine in plaque destabilization and acute
cardiovascular events [112]. Likewise, elevated visfatin levels
in PCOS may also signal heightened cardiovascular risk in
certain womenwith this syndrome, particularly in those with
insulin resistance.
Given its associations with insulin resistance and vascular
inflammation, several studies have been undertaken to elu-
cidate the role of visfatin in PCOS. Higher levels of serum
visfatin and visfatin mRNA in adipocytes have been reported
in PCOS women compared to BMI-matched controls [106,
107, 113–115]. Serum visfatin levels were found to correlate
with BMI [106, 113], insulin resistance [106, 107, 116], free
androgen index [107], and LH levels [115].
It has been observed that metformin treatment for 3
months lowered visfatin levels [114]. However, the investiga-
tions demonstratedmany interstudy variations in parameters
such as BMI, IR, FAI, and LH that significantly correlated
with visfatin levels in some studies but not in others. These
variations may be attributed to the small number of partici-
pants, less than 30 PCOS women in all but one [107] of these
investigations, and to interracial variations in the phenotypic
expression of PCOS [106].
More recent studies have reported no differences in
visfatin levels between PCOS women and controls [117, 118],
therefore necessitating further inquiries with more partici-
pants to clarify the role of this adipokine in PCOS.
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4.4.4. Chemerin. Chemerin is a chemotactic protein secreted
by adipocytes [119, 120] that is necessary for adipocyte
differentiation [121]. It is able to attract macrophages, which
express the chemerin receptor CMKLR1 (chemokine-like
receptor 1) [122]. In view of its chemoattractant proper-
ties, this adipokine may be one factor underlying the link
between obesity and chronic inflammation [122]. Chemerin
also induces insulin resistance in peripheral tissues such
as skeletal muscle by activation of ERK-1/2 and NF-𝜅B
pathways, culminating in inhibited cellular glucose uptake
[120]. Insulin stimulates chemerin secretion, promoting a
vicious circle increasing insulin resistance [106]. This protein
is thought to possibly present a link between obesity and
diabetes [120]. Serum chemerin levels have been found to
correlate with BMI [119, 120], WHR [119, 120], triglycerides
[119], elevated blood pressure [119], and adipocyte volume
[120].The latter has been found to be higher in PCOSpatients,
even in lean PCOS patients when compared to BMI-matched
controls [28]. Chemerin levels in PCOS are consequently
of interest, as this may be one of the factors underlying
the insulin resistance so common in PCOS. Chemerin is
also implicated in inflammation, which may be responsible
for vascular damage leading to CVD. Chemerin levels have
been reported to be higher in obese PCOS women than in
BMI- and WHR-matched controls [106, 123] as well as in
lean PCOSwomen compared to BMI-matched controls [123].
Treatment of the PCOSpatients withmetformin for 6months
has lowered chemerin levels and improved insulin resistance,
without changing BMI [106].
4.5. Proinflammatory and Macrophage-Derived Factors. This
section presents a survey of macrophages and proinflamma-
tory factors such as tumor necrosis factor-alpha (TNF-𝛼), C-
reactive protein (CRP), and interleukin-6 (IL-6).
4.5.1. Macrophages. Adipose tissue inflammation mediated
by activated tissue macrophages (ATMs) is a major pathway
culminating in the development of obesity-related insulin
resistance [124, 125]. CD11c is a marker specific to these
ATMs that infiltrate adipose tissue in obese individuals and
secrete cytokines such as TNF-𝛼 and IL-6, both of which are
associated with insulin resistance. In contrast, the markers
CD206, CD14, and CD163 are expressed by less inflamma-
torymacrophages [125]. CD11c-expressingmacrophages clus-
ter around dead adipocytes, forming histologically defined
crown-like structures (CLS) [125]. The density of CLS has
been found to correlate with the degree of insulin resistance
and obesity [125]. CD11c and CLS density is significantly
higher in lean and obese PCOS women than in BMI-
comparable non-PCOS controls [42]. The observation that
CD11c macrophages and CLS occur more frequently in obese
men than in obese women has led to the suggestion that
the increase observed in lean and obese PCOS women is
likely a result of hyperandrogenism [42]. CD11c adipose
tissue infiltration and CLS may be an early change in lean
hyperandrogenic PCOS women leading to the development
of insulin resistance in this group [42] that is comparable to
the insulin resistance in obese controls [19].
4.5.2. Proinflammatory Factors. TNF-𝛼 plays a role in the
pathogenesis of insulin resistance [126]. It inhibits tyrosine
phosphorylation of the insulin receptor and of IRS-1 in
muscle and fat cells [126] and has also been shown to down-
regulate the expression of the GLUT4 transporter necessary
for cellular entry of glucose [127]. Serum levels of TNF-𝛼 are
elevated in both obesity and DM2 [126]. Studies report that
TNF-𝛼 levels in PCOS correlatewith BMI [26, 27, 50, 128] and
that circulating TNF-𝛼 levels are elevated in both nonobese
[26, 129] and obese [27] PCOS women when compared
with BMI-matched controls. However, in other studies, these
differences in the levels of TNF-𝛼 between PCOSwomen and
controls diminished after adjusting for BMI and abdominal
adiposity [50, 128], thus questioning whether TNF-𝛼 eleva-
tions are related to PCOS or are a function of excess adiposity.
A meta-analysis found no significant difference in TNF-𝛼
levels between PCOS subjects and BMI-matched controls
[10]. However, the authors caution against overinterpretation
of these results, as their study also revealed evidence of a
publication bias favoring publication of studies that underes-
timate the differences in TNF-𝛼 levels between PCOSwomen
and controls [10]. An important difference between PCOS
and control subjects may lie in the TNF-𝛼 receptor [130].
Most of the metabolic effects of TNF-𝛼 are mediated through
the TNF-𝛼 receptor 2 [130]. AlthoughTNF-𝛼 receptor 2 levels
were increased in obesity, no differences in levels of this
receptor were observed between PCOS women and controls
[130]. However, a methionine 196 arginine polymorphism
in exon 6 of the gene encoding the TNF-𝛼 receptor 2 was
reported to be significantly more frequent in women with
PCOS than in controls, suggesting that TNF-𝛼 plays a role
in the development of metabolic pathologies in PCOS and
that this might be related to a structural change in the TNF-
𝛼 receptor that confers a more responsive phenotype, rather
than to circulating TNF-𝛼 levels or to the density of TNF-
𝛼 receptors per se [130]. Authors agree that larger and more
highly powered studies are needed to clarify the role of TNF-
𝛼 in PCOS [10, 130].
CRP has been proven to be a strong independent predic-
tor of cardiovascular events in healthy asymptomatic as well
as symptomatic women in the general population [131, 132].
Obesity is associated with elevations in CRP [133]. A meta-
analysis of 26 studiesmatching carefully for BMI revealed that
CRP is elevated in PCOS independently of obesity [10]. This
elevation of CRP in PCOS is more pronounced when obesity
is present, further heightening the risk of cardiovascular
events in this group of women [10]. However, the authors
caution against overattributing increased cardiovascular risk
to PCOS per se because, after adjusting for BMI, the elevation
in CRP attributable to PCOS is relatively small [10].
Interleukin-6 (IL-6) is released by mononuclear leuco-
cytes and adipose tissue [10], with levels being elevated in
obesity [10]. It directly stimulates hepatic CRP synthesis [10].
Although IL-6 elevations have been reported in lean and
obese PCOS women in relation to BMI-comparable controls
[10], a recent meta-analysis proved no significant difference
in circulating IL-6 levels between PCOS women and BMI-
matched controls [10], suggesting that elevated IL-6 in PCOS
is primarily related to obesity. However, a promoter region
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polymorphism (G/C) at position -174 of the gene encoding
IL-6 has been found to be strongly associated with DM2 in
theCaucasian population [134].This same polymorphismhas
been reported to occur more frequently in PCOS patients
[135, 136]. Furthermore, a certain microsatellite CA-repeat
polymorphism in the locus encoding the 𝛼-subunit of the
IL-6 receptor is associated with obesity, while the Arg148
allele in the region encoding the gp130 subunit of the IL-6
receptor gene is more common in normoandrogenic subjects
than hyperandrogenic ones [137].These observations suggest
that genetically determined hypersignaling defects in the IL-
6 receptor, rather than only circulating IL-6 levels, may be
implicated in the pathogenesis of metabolic hyperandrogenic
disorders such as PCOS [137]. However, relatively little is
known about this field and authors agree that larger studies
are needed [10, 137].
4.6. Dyslipidemia. Dyslipidemia is the most common
metabolic abnormality in PCOS [4, 8], and polycystic
ovary syndrome is the leading cause of dyslipidemia in
reproductive-age women [138]. Observations of PCOS
affected women and their relatives have shown that the
probability of developing dyslipidemia is 1.8-fold larger in
the PCOS individuals [8]. Overall, studies of PCOS patients
report slightly decreased levels of cardioprotective HDL-C,
with slightly elevated levels of TG, VLDL-C, and LDL-C
[4, 8]. PCOS women display the lipid profile observed
in insulin resistant states such as DM2 and characterized
specifically by elevated TG and lowered HDL-C [8, 71]. The
main determinant of heart disease risk is the total cholesterol
(TC) to HDL-C ratio [51]. This ratio is also slightly elevated
in PCOS patients [8].
Elevated LDL-C [71, 139–141] and VLDL-C [139] in PCOS
are further elevated when excess adiposity is present, but, as
confirmed by a recent meta-analysis, the higher levels occur
in PCOS independently of obesity [142]. Elevated LDL-C
levels are linked with hyperandrogenemia [139, 140, 143]. It
is unclear whether hyperandrogenemia and elevated LDL-C
have a causal relationship or whether these are closely related
genetic traits inherited together [140].
Although LDL-C and VLDL-C are elevated in PCOS
independently of obesity, obesity is thought to be the major
determining factor for elevations in TG levels and for the
reduction ofHDL-C levels that are observed in PCOS [71, 140,
142, 144]. In a study comparing lipid profiles between PCOS
probands, their sisters with andwithout PCOmorphology on
ultrasound, and controls, the elevated TG levels and reduced
HDL-C levels in probands relative to the other groups
disappeared after controlling for BMI [144], suggesting that
BMI is the predominant determinant of TG and HDL-C
levels in PCOS [144], both of which are strong independent
risk factors for death from cardiovascular disease [145].
However, after adjustment for BMI, age, and centripetal
obesity in another large study of PCOSwomen, HDL-C levels
still remained significantly lower in PCOS women when
compared to controls, though only slightly so [146]. This
indicates that factors other than BMI and centripetal obesity
are contributors to the lowering of HDL-C levels in PCOS
women, although, of course, BMI is observably a significant
determinant of lipid profiles [146].
In a study that did not control for diet, HDL-C levels were
unexpectedly higher in obese PCOS women than in obese
controls [71]. This inconsistency signals that, in addition
to BMI [144], other factors such as age, ethnicity, genetic
influences, and environment also modulate lipid profiles of
women with PCOS [15, 71, 141, 147]. The importance of envi-
ronmental (diet and activity level) and genetic contributions
to dyslipidemia is evidenced by the fact that TG elevations in
American PCOS women compared to Italian PCOS women
persist even after controlling for BMI [15, 147].
Even PCOS women with normal lipid profiles may be
at increased risk of cardiovascular events. This is because
significantly higher levels of lipoprotein-a and a higher
proportion of small, dense LDL have been found in PCOS
patients compared to controls [148], although TC and total
LDL-C levels did not differ between PCOS and control
women [148]. This similarity in TC and total LDL-C levels
makes the PCOSwomen appear to have normal lipid profiles.
SuchPCOSwomen are at higher risk of cardiovascular events,
because certain lipoproteins, such as lipoprotein-a and small,
dense LDL-C, are more atherogenic [148].
Another atherogenic shift in PCOS is the lipid-to-protein
ratio of HDL-C particles. The lipid-to-protein ratio in an
HDL-C particle reflects the capacity of the particle to remove
cholesterol from tissues [149]. A reduction of this ratio signals
a decreased or impaired capacity to remove cholesterol and
prevent atherosclerosis [149].
In one study, the lipid-to-protein ratio in the HDL-C
was found to be lower in obese PCOS women than in obese
women without PCOS [149].The latter finding signals a drop
in the antiatherogenic properties of HDL-C of PCOS women
[149].
Despite slight changes in lipid profiles in PCOS, most
women with PCOS are young and have normal blood
pressure and hence do not qualify for primary prevention of
cardiovascular disease [8]. Nevertheless, performing at least
one measurement of lipid profiles in PCOS in conjunction
with an assessment for other cardiovascular risk factors such
as smoking and family history of CVD is suggested [8].
4.7. Traditional and Novel Cardiovascular Risk
Factors in PCOS
4.7.1. Traditional Cardiovascular Disease Risks Factors in
PCOS. Traditional risk factors for cardiovascular disease,
such as IGT, DM2, dyslipidemia, obesity, and elevated blood
pressure, are more prevalent in women with PCOS than in
control women of similar age [51].
4.7.2. Markers of Atherosclerosis. Calcification of the coro-
nary arteries assessed by electron beam computed tomog-
raphy correlates with the degree of atherosclerosis found
on histopathological exam and was found to predict the
incidence of cardiovascular events in asymptomatic women
[150]. The prevalence and extent of coronary artery calcifi-
cation (CAC) were found by several studies to be higher in
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both younger (aged 30 to 45 years) and older (aged over 40
years) women with PCOS than in controls, independently
of age and BMI [151–153]. It has been suggested that the
reported increase in CAC among PCOS women is related
to the parameters that were different in PCOS women in
relation to the control women in the studies: increased
LDL-C [151, 153], lower HDL-C [153], and hyperinsulinemia
[153]. Among the women with PCOS, BMI was a significant
predictor of whether the women would have CAC [151–
153], leading to the suggestion that obese women with PCOS
should be targeted for aggressive treatment and prevention of
cardiovascular disease [151, 152]. Talbott et al. also reported
a higher prevalence and extent of aortic calcification (AC)
in women with PCOS [153]. The investigators of the latter
study found that total testosterone was an independent risk
factor for greater AC [153]. In animal models, testosterone
exacerbated atherosclerosis in female monkeys but conferred
a protective effect in males [153]. Similarly, a large study
reported that men with the highest total testosterone levels
had a reduced risk of AC, but, conversely, women with
elevated testosterone levels had the highest risk for CAC [153,
154], leading authors to suggest that the aorta in women may
be more sensitive to the effects of endogenous testosterone
[153, 154].
Increased intima-media wall thickness (IMT) is an early
marker of atherosclerosis [155]. Increased carotid intima-
media wall thickness (CIMT) is also a strong independent
predictor of the occurrence of major cardiovascular events
later in life [155]. Higher CIMT has been reported in both
younger (age 20 to 35 years) [57, 156] and older (over 45 years)
[153] patients with PCOS in comparison to controls of similar
age and BMI. A recent meta-analysis indicated that women
with PCOS had a 0.072 to 0.084mm higher CIMT compared
to controls [157]. Every 0.10mm increase in CIMT has been
estimated to increase the risk of a myocardial infarction (MI)
by 15% and the risk of stroke by 18% [157]. The increase in
CIMT in PCOS relative to controls of comparable age and
BMIhas been associated in different studieswith higher levels
of insulin [57], hyperandrogenism [156], Il-18 [157], LDL-C
[157], and abdominal obesity [157], although the contribution
of each of these factors to increased CIMT in PCOS has
not been systematically evaluated [157]. However, CIMT
increases with age in PCOS, as in the general population
[157].
4.7.3. Vascular Endothelial Dysfunction. Several studies have
demonstrated decreased brachial artery flow-mediated dila-
tion (FMD), a marker of endothelial function, in young
normal weight, overweight, and obese women with PCOS
compared to body mass matched controls [9, 17]. The
decreased FMD was observed even in normal weight PCOS
women who were also normotensive and had normal lipid
profiles [9] and who therefore lacked many of the traditional
cardiovascular risk factors [9]. It is considered that elevated
androgen levels in the PCOS women relative to controls
contribute to the observed decline in endothelial function
[57].
An earlier study by Paradisi et al. further supports the
role of elevated androgen levels in precipitating endothelial
dysfunction [158]. When obese PCOS and control women of
similar age, BMI, LDL-C, and TC levels received intrafemoral
artery infusions of the endothelial-dependent vasodilator
methacholine chloride (MCh), the leg blood flow was 50%
less in the PCOSwomen compared to the controls, suggesting
impaired nitric oxide (NO) production in the endothelial
cells of PCOS women [158]. The degree of decrease in leg
blood flow was strongly associated with free testosterone
levels [158]. This, in conjunction with the observation that
androgen deprivation in men has enhanced endothelial-
dependent vasodilation [159], initially led to the suggestion
that elevated androgen levels in PCOSwomenmay be amajor
contributor to endothelial dysfunction and macrovascular
disease [158].
Several molecules implicated in endothelial dysfunction
have been linked to PCOS. A recent meta-analysis indicated
that homocysteine, a mediator of endothelial injury, is in
higher levels in PCOS women than in controls of similar age
and BMI [160]. The same study also demonstrated that levels
of asymmetric dimethylarginine (ADMA), a competitive
inhibitor of endothelial NO synthase and an independent
risk marker for cardiovascular morbidity and mortality [161],
are higher in PCOS women than in age- and BMI-matched
controls [160]. Several studies have found that, in comparison
to age- and BMI-comparable control women, PCOS women
also exhibit elevated levels of endothelin-1 [6, 57], a by-
product of endothelial damage and a potent vasoconstric-
tor [57]. Plasminogen activator inhibitor-1, which inhibits
fibrinolysis and in higher levels predisposes to accelerated
development of atherosclerosis [162], has been shown to be
elevated in normal weight young PCOS women relative to
controls [163].
4.7.4. Coagulation and Fibrinolytic Disturbances. Distur-
bances in circulating markers of coagulation and fibrinol-
ysis may contribute to cardiovascular disease risk. Several
studies observed dysregulation of the hemostatic system,
particularly hypofibrinolysis, hypercoagulability [163, 164],
and endothelial and platelet dysfunction, in women with
PCOS [164, 165]. The potential mechanisms of coagulation
disturbances remain to be elucidated. It has been observed
that women with PCOS have high circulating concentrations
of PAI-1 and fibrinogen, independent of age and BMI,
correlated with low SHBG and high insulin levels [166].
Hyperinsulinemia impairs fibrinolysis by enhancing PAI-1
secretion and by inhibiting hepatic production of SHBG
[167]. Our group recently observed strong negative linear
association between serum SHBG and CRP levels, even
following adjustment for BMI, WHR, TT, HOMA-IR, total
cholesterol, LDL cholesterol, and triglyceride levels [168].
High CRP and sE-selectin were recently observed as the
strongest explanatory factors of high fibrinogen levels in
women with PCOS [166]. Strong positive correlation is
recognized between hyperandrogenism and hypofibrinolysis
in women with PCOS contributing to a prothrombotic state
[163].
4.7.5. Cardiac Dysfunction. Studies report that, compared
to age- and BMI-matched controls, young PCOS women
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have increased left ventricular mass index (LVMi) [61], a
predictor of CVDmorbidity andmortality [8], and decreased
diastolic filling [61, 169]. Both of these abnormalities occur
independently of excess weight, presenting in lean as well as
overweight and obese PCOSpatients. Additionally, decreased
left ventricular ejection fraction has been reported in young
overweight and obese women with PCOS compared to
controls [61].
4.7.6. The Risk of Cardiovascular Events in PCOS. Even
though many studies have shown an elevation in surrogate
biomarkers of cardiovascular disease in PCOS women, the
question remains as to what extent this translates into more
frequent or earlier events. Only a few prospective epidemio-
logical studies have addressed this question.
A 49-year follow-up study of 786 women diagnosed with
PCOS based only on ovarian wedge section found that the
risk of fatal cardiovascular events was not different between
PCOS women and controls [170]. Similarly, a prospective 21-
year follow-up study of 31 women with histologically verified
Stein-Leventhal syndrome found that although the CVD
risk factors hypertension and hypertriglyceridemia were still
more prevalent among the PCOS women in postmenopausal
age, these women did not have an increased risk of suffering
MI, stroke, or death caused by CVD compared to non-
PCOS women [171]. A retrospective study of 319 women
diagnosed with PCOS based on more stringent criteria
(an/oligoovulation and hyperandrogenism) reported that
there was no difference in cardiovascular mortality risks
between PCOS women and age-matched controls [172],
although the PCOS women demonstrated a higher risk of
nonfatal cerebrovascular events, even after adjustment for
BMI [172].
Another investigation followed 82,439 women aged 20–
35 for 14 years [173]. Compared with women reporting a
history of regular menses, women reporting a history of very
irregular menses had a significantly higher risk of nonfatal
and fatal cardiovascular disease, even after adjustment for
BMI, age, menopausal status, and smoking [173]. Although
these women were not diagnosed with PCOS, it is estimated
that 80–90% of women reporting menstrual irregularity have
PCOS [8]. Furthermore, a recent meta-analysis indicated a
2-fold increased risk of coronary heart disease (CHD) and
stroke for patients with PCOS relative to women without
PCOS [174]. The meta-analysis found that there is a 55%
increase in the risk for CHD and stroke in PCOS women
using only studies that adjusted for BMI, showing that BMI
is not the sole cause of increased risk of cardiovascular events
in women with PCOS [174].
The risk of cardiovascular events also appears to be higher
in postmenopausal womenwith a history of PCOS than those
without. The Women’s Ischemia Syndrome Evaluation study
reported that the cumulative 5-year event-free survival for
women without a history of PCOS is 88.4% and only 78.9%
for those with a premenopausal history of PCOS [175].
A retrospective study found similar results. The study
evaluated the incidence of CV events (MI, angina, heart
failure, stroke, and CV death) in a cohort of 2300 PCOS
women between 1988 and 2009 [176]. Overall, CV eventswere
not any more prevalent in the cohort than in the local female
population [176]. However, when the cohort was stratified
by age and comparisons were limited to age-similar groups
in the local female population, PCOS showed an association
with CV events within each age group [176]. The age-specific
prevalence of CV events was significantly higher in PCOS
patients over 45 compared with the local female population,
with odds ratio as high as 12.88 in women over 65 with a
premenopausal history of PCOS [176]. Factors in the cohort
associated with an increased risk of CV events were age,
hypertension, obesity, smoking, and having DM2 [176].
5. Conclusions
This review has provided a survey of many intrinsic causative
factors that underlie IR, obesity, and the other metabolic per-
turbations associated with PCOS. Future investigations may
elucidate which of these intrinsic causative factors are present
in the different phenotypic subgroups of PCOS women.
Further studies may also delineate which of these intrinsic
factors are more common in certain geographic regions and
associated ethnicities. Finally, andmore importantly, through
future investigations we may gain an understanding of which
of these causative factors are associated with the most severe
consequences.This may help foster a better understanding of
the pathophysiology underlying PCOS in different subgroups
and populations. Such knowledge could then be leveraged to
devise the most optimal screening and effective management
for women from different subgroups and ethnicities.
Experts have advocated the annual screening of all PCOS
women for IGT with the OGTT and more frequent screen-
ings for those with other DM2 risk factors, such as a family
history of DM2. Some investigators have also suggested
screening lean women with DEXA for excess abdominal fat
accumulation, as lean PCOSwomenwith a higher proportion
of abdominal fat relative to BMI-comparable control women
aremore susceptible to developing insulin resistance andmay
therefore benefit from more aggressive prevention.
Central abdominal fat accumulation has been associated
with insulin resistance, chronic inflammation, and harmful
ectopic fat accumulations. Studies evaluating abdominal fat
accumulation in PCOS women relative to BMI-comparable
controls have reported contradictory results. This highlights
the need for more studies that would quantify ectopic,
visceral, and subcutaneous abdominal fat by CT or MRI, in
order to provide definitive answers about the relationship
between PCOS and visceral fat.
Uncertainty also remains in PCOS regarding the inci-
dence of cardiovascular disease later in life, despite the
indisputable presence of multiple CV risk factors earlier in
the lifespan. Therefore, prospective observational trials are
urgently needed that follow patients diagnosed with PCOS
based on strict inclusion criteria and that track these women
from a young age until after menopause.
The most urgent problem with the current management
of PCOS is that many doctors focus on the short-term cos-
metic and reproductive consequences, while metabolic and
psychological risks are often not considered. Indeed, current
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knowledge clearly indicates that metabolic complications are
present in both lean and obese women with PCOS. Early
screening and close follow-up are therefore encouraged in
both groups of patients.
Also, the observed trends of insulin resistance incidence
and early cardiovascular event occurrences within families
point to the conclusion that the family members of PCOS
women should probably be screened for metabolic distur-
bances.
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